CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).

    LOS ANGELES, CA, June 19 /CNW/ - Canopus BioPharma, Inc. (OTC: CBIA), has
confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing
agent and has also demonstrated the synergistic effect of this drug in
combination with both cisplatin and cetuximab (Erbitux) in two mice lung
cancer models.
    Chairman of Canopus BioPharma, Dr. Patrick Prendergast, stated, "We at
Canopus are encouraged with the discovery of this new use for CB1400 to
increase efficacy and reduce toxicity issues associated with conventional
chemotherapeutic agents."
    CB1400, a former schistosomal drug, is currently in phase II clinical
development as an anti-mucositis preventative agent in patients receiving
radio- and/or chemotherapy treatment. Current anti-mucositis drugs have shown
tumor-protective properties. For this reason CB1400 was evaluated by Canopus
to determine its effect on tumor growth.
    In work carried out by the Harvard School of Dental Medicine, Boston, on
behalf of Canopus BioPharma, it was confirmed that CB1400 as a single agent
significantly reduces tumor growth. In an initial study, tumor growth was
inhibited by 48.8% in mice treated with cisplatin, the most commonly used
chemotherapy drug. CB1400 alone showed 62.3% tumor growth inhibition while the
combination of both compounds further increased inhibition to 69.6%, thus
confirming a synergistic effect between cisplatin and CB1400. In addition,
there was no evidence of toxicity based on observations of survival and weight
change in the mice and there was no evidence that CB1400 protected the tumor.
    Cisplatin is a platinum-containing chemotherapeutic drug, administered by
IV injection which has been used for more than 30 years to treat various forms
of cancer. Enhanced efficacy with CB1400 may prevent the development of drug
resistance that is common with cisplatin.
    In a similar study, tumor growth was inhibited by 61% in mice treated
with cetuximab (Erbitux) alone. An almost 30% increase in efficacy was
observed with the addition of CB1400 to cetuximab, increasing tumor inhibition
to 89.4%, confirming a synergistic effect of combining the two anti-tumor
drugs. Similar to the cisplatin study, there was no significant difference in
mean weight or survival between the groups of mice; and no toxicity was
observed in this study.
    Cetuximab is a chimeric monoclonal antibody, an epidermal growth factor
receptor inhibitor used as a chemotherapeutic agent, administered by IV
injection for the treatment of various cancers. Enhancing the efficacy of
cetuximab may have potential in treating patients no longer responding to
traditional chemotherapy.

    About Canopus BioPharma, Inc.:

    Canopus BioPharma, Inc. (OTCBB: CBIA) is dedicated to providing the
safest, most cost effective and efficacious pharmaceutical products and assay
methods in the areas of infectious disease, radiation protection, cancer, and
addiction. With innovative science, proven research and development
leadership, and superior products and compounds, Canopus BioPharma has, since
2001, been committed to becoming a market trend setter in a new era of
healthcare. In addition, the Company is a world leader in the development of
novel camelid antibody products to provide unique avenues of progress and
improvement in assay methods and monitoring capabilities for physicians,
patients and researchers, initially for food chain protection applications.
Canopus maintains staff in Australia, South Africa, Ireland, Panama and the
USA. Additional information on the Company is available at

For further information:

For further information: Canopus BioPharma Contact: Len Rothstein,
President, Tel. (818) 980-5008, Fax. (818) 980-5088, len@canopusbiopharma.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890